{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:24:12Z","timestamp":1769171052494,"version":"3.49.0"},"reference-count":44,"publisher":"Portland Press Ltd.","issue":"4","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":738,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,31]]},"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune disease commonly treated with immunosuppressants. We evaluated the novel immunosuppressant, rapamycin (RAPA), in a rat model of experimental autoimmune MG (EAMG). Mortality rates in the RAPA (12%) were significantly down compared with the EAMG (88%) or cyclophosphamide (CTX) (68%) intervention groups. Muscular weakness decreased after both RAPA and CTX treatment. However, Lennon scores were lower (1.74 \u00b1 0.49, 3.39 \u00b1 0.21, and 3.81 \u00b1 0.22 in RAPA, CTX, and EAMG groups, respectively), and body weights (203.12 \u00b1 4.13 g, 179.23 \u00b1 2.13 g, and 180.13 \u00b1 5.13 g in RAPA, CTX, and EAMG groups, respectively) were significantly higher, only in the RAPA group. The proportion of regulatory T cells (Treg) significantly increased, while that of Th17 cells significantly decreased in the RAPA group compared with the EAMG group. In comparison, CTX intervention resulted in increased Th17 but significantly decreased Tregs. Hence, RAPA can be more effectively used in comparison with CTX to treat MG, with an efficacy higher than that of CTX. In addition, our results suggest RAPA\u2019s efficacy in alleviating symptoms of MG stems from its ability to correct the Treg\/Th17 imbalance observed in MG.<\/jats:p>","DOI":"10.1042\/bsr20170767","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:10:31Z","timestamp":1498608631000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Rapamycin alleviates inflammation and muscle weakness, while altering the Treg\/Th17 balance in a rat model of myasthenia gravis"],"prefix":"10.1042","volume":"37","author":[{"given":"Feng","family":"Jing","sequence":"first","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing 100853, China"},{"name":"Department of Neurology, The 309th Hospital of Chinese PLA, Beijing 100091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xusheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"2021111618512091900_B1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-9255-9-20","article-title":"Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis","volume":"9","author":"Soltys","year":"2012","journal-title":"J. Inflamm. (Lond.)"},{"key":"2021111618512091900_B2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2021111618512091900_B3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"2021111618512091900_B4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2567.2005.02220.x","article-title":"Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment","volume":"116","author":"Fattorossi","year":"2005","journal-title":"Immunology"},{"key":"2021111618512091900_B5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"2021111618512091900_B6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"2021111618512091900_B7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","article-title":"T helper type 17 cells expand in patients with myasthenia-associated thymoma","volume":"76","author":"Wang","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"2021111618512091900_B8","doi-asserted-by":"crossref","first-page":"219S","DOI":"10.1016\/S0041-1345(03)00222-7","article-title":"Preclinical results of sirolimus treatment in transplant models","volume":"352","author":"Stepkowski","year":"2003","journal-title":"Transplant. Proc."},{"key":"2021111618512091900_B9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ni.1760","article-title":"Foxp3+ regulatory T cells: differentiation, specification, subphenotypes","volume":"10","author":"Feuerer","year":"2009","journal-title":"Nat. Immunol."},{"key":"2021111618512091900_B10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"2021111618512091900_B11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaut.2011.02.006","article-title":"PI3Kdelta drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation","volume":"36","author":"Haylock-Jacobs","year":"2011","journal-title":"J. Autoimmun."},{"key":"2021111618512091900_B12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1124\/pr.110.004051","article-title":"Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory\/autoimmune diseases and hematological malignancies","volume":"64","author":"Foster","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"2021111618512091900_B13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2004-829593","article-title":"The epidemiology of myasthenia gravis","volume":"24","author":"Phillips","year":"2004","journal-title":"Semin. Neurol."},{"key":"2021111618512091900_B14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2249.1997.d01-881.x","article-title":"Age- and sex-related resistance to chronic experimental autoimmune myasthenia gravis (EAMG) in Brown Norway rats","volume":"107","author":"Hoedemaekers","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"2021111618512091900_B15","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.4049\/jimmunol.140.10.3406","article-title":"Resistance to experimental autoimmune myasthenia gravis in genetically inbred rats. Association with decreased amounts of in situ \u2013antibody complexes","volume":"140","author":"Biesecker","year":"1988","journal-title":"J. Immunol."},{"key":"2021111618512091900_B16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.expneurol.2015.03.010","article-title":"Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californicas\u2013recommendations for methods and experimental designs","volume":"270","author":"Losen","year":"2015","journal-title":"Exp. Neurol."},{"key":"2021111618512091900_B17","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.)","year":"2011","edition":"8th edn"},{"key":"2021111618512091900_B18","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.4049\/jimmunol.172.4.2697","article-title":"Breakdown of tolerance to a self-peptide of alpha-subunit induces experimental myasthenia gravis in rats","volume":"172","author":"Baggi","year":"2004","journal-title":"J. Immunol."},{"key":"2021111618512091900_B19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"Christadoss","year":"2000","journal-title":"Clin. Immunol."},{"key":"2021111618512091900_B20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1034\/j.1600-065x.2001.1840111.x","article-title":"Rat models as tool to develop new immunotherapies","volume":"184","author":"Link","year":"2001","journal-title":"Immunol. Rev."},{"key":"2021111618512091900_B21","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1084\/jem.141.6.1365","article-title":"Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs","volume":"141","author":"Lennon","year":"1975","journal-title":"J. Exp. Med."},{"key":"2021111618512091900_B22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410110109","article-title":"Nerve stimulation test in murine experimental autoimmune myasthenia gravis","volume":"11","author":"Pachner","year":"1982","journal-title":"Ann. Neurol."},{"key":"2021111618512091900_B23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"key":"2021111618512091900_B24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav. Res. Methods"},{"key":"2021111618512091900_B25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.autrev.2011.05.004","article-title":"Human FoxP3+ regulatory T cells in systemic autoimmune diseases","volume":"10","author":"Miyara","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"2021111618512091900_B26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMra055446","article-title":"Regulation of immune responses by T cells","volume":"354","author":"Jiang","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2021111618512091900_B27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","article-title":"Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease","volume":"212","author":"Sakaguchi","year":"2006","journal-title":"Immunol. Rev."},{"key":"2021111618512091900_B28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2007.10.001","article-title":"Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis","volume":"126","author":"Li","year":"2008","journal-title":"Clin. Immunol."},{"key":"2021111618512091900_B29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.imlet.2008.11.015","article-title":"The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis","volume":"122","author":"Zhang","year":"2009","journal-title":"Immunol. Lett."},{"key":"2021111618512091900_B30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clim.2013.05.009","article-title":"ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh\/Tfr helper cell profiles","volume":"148","author":"Xie","year":"2013","journal-title":"Clin. Immunol."},{"key":"2021111618512091900_B31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s10875-013-9965-3","article-title":"Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barre syndrome","volume":"34","author":"Han","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"2021111618512091900_B32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nature06878","article-title":"TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammaT function","volume":"453","author":"Zhou","year":"2008","journal-title":"Nature"},{"key":"2021111618512091900_B33","doi-asserted-by":"crossref","first-page":"823085","DOI":"10.1155\/2012\/823085","article-title":"Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new","volume":"2012","author":"Alunno","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"2021111618512091900_B34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jneuroim.2013.06.007","article-title":"Biased Treg\/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms","volume":"262","author":"Jamshidian","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"2021111618512091900_B35","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"2021111618512091900_B36","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/ndt\/gfp586","article-title":"Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs","volume":"25","author":"Bocian","year":"2010","journal-title":"Nephrol. Dial. Transplant"},{"key":"2021111618512091900_B37","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ni.2607","article-title":"Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways","volume":"14","author":"Kim","year":"2013","journal-title":"Nat. Immunol."},{"key":"2021111618512091900_B38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/nyas.12059","article-title":"Role of PI3K\/Akt and mTOR complexes in Th17 cell differentiation","volume":"1280","author":"Nagai","year":"2013","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2021111618512091900_B39","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.4049\/jimmunol.1000769","article-title":"Combined administration of a mutant TGF-beta1\/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance","volume":"185","author":"Zhang","year":"2010","journal-title":"J. Immunol."},{"key":"2021111618512091900_B40","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1042\/BST20130032","article-title":"Immune responses of macrophages and dendritic cells regulated by mTOR signalling","volume":"41","author":"Katholnig","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"2021111618512091900_B41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00105-011-2274-y","article-title":"Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus","volume":"63","author":"Krengel","year":"2012","journal-title":"Hautarzt"},{"key":"2021111618512091900_B42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.lungcan.2012.12.020","article-title":"The efficacy of tacrolimus and sirolimus in heavily pre-treated unresectable thymic malignancies","volume":"80","author":"Payne","year":"2013","journal-title":"Lung Cancer"},{"key":"2021111618512091900_B43","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1083\/jcb.200903131","article-title":"Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy","volume":"187","author":"Risson","year":"2009","journal-title":"J. Cell. Biol."},{"key":"2021111618512091900_B44","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.neures.2013.07.008","article-title":"Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK+) experimental autoimmune myasthenia gravis (EAMG)","volume":"77","author":"Chauhan","year":"2013","journal-title":"Neurosci. Res."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20170767\/480433\/bsr-2017-0767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20170767\/480433\/bsr-2017-0767.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T05:30:20Z","timestamp":1692855020000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/37\/4\/BSR20170767\/57234\/Rapamycin-alleviates-inflammation-and-muscle"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20170767","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]},"article-number":"BSR20170767"}}